Physician profile
Dena O Leary
NPI 1457532046
$34,864.67
in general payments reported to CMS, 2019-2025
21 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,775 · 2020: $613 · 2021: $436 · 2022: $757 · 2023: $494 · 2024: $16K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $3,743 · Food and Beverage: $2,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,099.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,400.00 |
| Travel and Lodging | $3,743.41 |
| Food and Beverage | $2,040.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,938.14 | 2022-2025 | |
| Medical Device Business Services, INC. | $8,563.20 | 2024 | Enseal, Harmonic |
| Ethicon US, LLC | $7,841.25 | 2023-2025 | Enseal, Harmonic, Monocryl |
| Boston Scientific Corporation | $1,644.74 | 2019-2025 | Advantage System, Bulkamid, Axonics |
| Karl Storz Endoscopy-America | $1,143.88 | 2025 | |
| Medtronic USA, INC. | $808.79 | 2019-2020 | |
| Astellas Pharma US INC | $568.54 | 2019-2023 | Veozah, Myrbetriq |
| Medtronic, INC. | $483.78 | 2021-2022 | |
| Ethicon Endo-Surgery INC. | $470.00 | 2025 | Harmonic, Enseal |
| Allergan, INC. | $100.89 | 2020-2022 | |
| Ambu INC. | $45.35 | 2025 | |
| Axonics, INC. | $40.21 | 2021-2023 | Bulkamid |
| Minerva Surgical, INC | $36.78 | 2023 | |
| Lupin INC. | $31.57 | 2019 | |
| Sage Therapeutics, LLC | $26.39 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $24.84 | 2023 | Irrisept |
| Vertical Pharmaceuticals, LLC | $22.59 | 2019 | |
| Pfizer INC. | $20.38 | 2019 | |
| Mission Pharmacal Company | $20.26 | 2021 | |
| Hologic Sales and Service, LLC | $20.10 | 2024 | Thinprep 2000 Processor, Aptima |
| Glaxosmithkline, LLC. | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dena O Leary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.